The recent report that, in two different gastric cancer cell lines, SNU5 and NCI-N87, the knockdown of RNF11 increases the sensitivity to gefitinib treatment strongly suggests RNF11 as a promising therapeutically exploitable target [117]. Here, RNF11 is linked to gastric cancer.